热门资讯> 正文
Eliem Therapeutics GAAP每股收益为-0.13美元，击败0.02美元
2025-03-26 04:38
- Eliem Therapeutics press release (NASDAQ:CLYM): Q4 GAAP EPS of -$0.13 beats by $0.02.
- Cash, cash equivalents and marketable securities were $212.5 million as of December 31, 2024, as compared to $106.8 million as of December 31, 2023. Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
More on Eliem Therapeutics
- Seeking Alpha’s Quant Rating on Eliem Therapeutics
- Historical earnings data for Eliem Therapeutics
- Financial information for Eliem Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
